Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A gene marker and a detection kit for predicting the clinical efficacy of methotrexate in the treatment of psoriasis

A technology of gene markers and detection kits, which is applied in the field of detection kits for predicting the clinical efficacy of methotrexate in the treatment of psoriasis, and achieves the effect of high treatment efficiency

Active Publication Date: 2019-01-15
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are few reports on gene polymorphisms related to MTX treatment of psoriasis, especially research on psoriasis susceptibility loci

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A gene marker and a detection kit for predicting the clinical efficacy of methotrexate in the treatment of psoriasis
  • A gene marker and a detection kit for predicting the clinical efficacy of methotrexate in the treatment of psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1: Observational experiments on the clinical curative effect and toxic and side effects of MTX in the treatment of psoriasis

[0017] Materials and Methods:

[0018] 1) Patients with psoriasis: Patients with psoriasis who visited the Psoriasis Clinic of the Department of Dermatology of Huashan Hospital from January 2015 to June 2017 were selected as observation objects.

[0019] 2) Medication intervention method: oral administration of MTX7.5mg once a week in the 1st and 2nd week of treatment, 10mg a single oral administration a week from the 3rd to 4th week, and 12.5mg a single oral administration a week from the 5th to 12th week.

[0020] 3) Inclusion criteria

[0021] (1) Age 18-60;

[0022] (2) Patients diagnosed with vulgaris, arthropathic, erythrodermic and pustular psoriasis, body surface area involved (BSA)>10% or psoriasis area and severity index (PASI)> 10;

[0023] (3) Fill out the complete epidemiological survey form and sign the informed consent...

Embodiment 2

[0035]Example 2 Correlation between psoriasis susceptibility genes and MTX clinical efficacy

[0036] Materials and methods: DNA was extracted from patients, and 18 non-HLA loci of 90 patients were genotyped using the sequenom platform. The effective group and the ineffective group were defined according to whether PASI75 reached 12w or not. Bioinformatics analysis showed that, The LCE3D genotype was statistically significant between the effective group and the ineffective group;

[0037] (1) Comparison of patient information between the effective group and the ineffective group of MTX treatment

[0038] Treated with MTX for 12 weeks to achieve PASI75 improvement as the effective group, the rest as the ineffective group, the effective group (19±12) was significantly longer than the ineffective group (14±11), the difference was statistically significant p<0.05;

[0039] The probability of the rs4112788AG genotype at the LCE3DSNP site was significantly higher in the effective g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biology, and relates to a gene marker and a detection kit for predicting the clinical efficacy of methotrexate in the treatment of psoriasis. A LCE3D SNP site rs4112788AG genotype is used as a gene marker for predicting that clinical efficacy of methotrexate in treating psoriasis. The relationship between the LCE3D SNP site rs4112788AG genotype and clinical efficacy of MTX in the treatment of psoriasis is studied. The results showed that rs4112788 genotype is related to clinical efficacy of MTX. The kit is provided to investigate the efficacy ofMTX therapy and the risk of hepatotoxicity in psoriasis patients with or without the rs4112788AG genotype at the LCE3D SNP locus, predict and evaluate the clinical efficacy of MTX in the treatment ofpsoriasis, thus guiding clinicians to formulate appropriate MTX treatment intervention program and providing a basis for improving the clinical efficacy of MTX.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to a detection kit for the curative effect of psoriasis drugs, in particular to a novel detection kit for predicting the clinical curative effect of methotrexate (MTX) in treating psoriasis. To detect the SNP site of the susceptibility gene LCE3D in patients with psoriasis and predict the clinical efficacy of MTX. It can guide clinicians to formulate a suitable MTX treatment intervention plan, and provide a basis for improving the clinical efficacy of MTX. Background technique [0002] The prior art discloses that psoriasis is a common chronic inflammatory disease that can affect multiple organs such as skin, nails, joints, kidneys, and cardiovascular. Due to the high incidence of the disease, long course of disease, easy recurrence, and difficult to cure, it brings serious physical and mental damage and economic burden to patients. Among the drug interventions commonly used in clinical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/106C12Q2600/172C12Q2600/156
Inventor 徐金华颜克香张学军
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com